ATHN DATA SUMMIT 2016

ATHN 2 Investigators Breakfast Breakout

Janna Journeycake, MD

Moderator

athn™ american thrombosis & hemostasis network | 10 CELEBRATING ten years

A Longitudinal, Observational Study of Previously Treated Hemophilia Patients (PTPs) Switching Factor Preparations

"Factor Switching Study"

2

athn™ american thrombosis & hemostasis network | 10 CELEBRATING ten years

Agenda:

Project Update
Ellis Neufeld, MD, PhD, Chair, ATHN 2 Steering Committee

Site Best Practices for ATHN 2 Study Success
Systematic Screening to Identify ATHN 2 Patients
Judith Kadosh, RN BSN,
Hemophilia Center of Western Pennsylvania

Managing the ED10 Inhibitor Test
Erin Cockrell, DO,
St. Joseph's Children's Hospital

Project Update

Ellis Neufeld, MD, PhD

Chair, ATHN 2 Steering Committee

athn™ american thrombosis & hemostasis network | 10 CELEBRATING ten years

ATHN 2 RESEARCH STUDY

ATHN 2 Objectives

- To assess inhibitor development and strength based on Bethesda Units (BU) within one (1) year or fifty (50) exposure days, after switching factor replacement products in PTPs
- Secondary:
  - To describe prospective incidence, prevalence, risk factors of inhibitor development, bleeding, current dosing regimens, EUHASS safety and efficacy data in this population
  - To summarize factor replacement dosing regimens prescribed
  - To serve as a platform for product-specific questionnaires

Study Population

600 Hemophilia Patients Receiving Care at HTCs



Study Update

ATHN 2 Timeline

Plan for up to 30 Sites, 600 Subjects



ATHN 2 Accrual

As of August 31, 2016 – 30 Sites Invited; 22 Open/Enrolling



ATHN 2 Accrual by Site and Arm
As of August 31, 2016



ATHN 2 Study Summary
as of August 31, 2016

Metric	#	%
Total Accrual	56 / 600	9.3%
Product Specific Modules Open	5	
Number of Patients Completed Study	9	1.7 %
Number of SAEs / Inhibitors	0 / 0	

ATHN 2 Product-Specific Modules

Post Approval Data; Additional Compensation by Module

Biogen

Status: Open

- Eloctate®
- Alprolix ®

Shire (Baxalta)

Status: Released to Sites 8/31

- Adynovate ®

CSL-Behring

Status: Released to Sites 8/31

- Idelvion®
- Afstyla®

Future Modules

Status: In Development

Product-Specific Modules - Schedule of Assessments
See Notes for Timing and Administration of Questionnaires

Notes:

1. For ARM B (Retrospective). For some patients, Baseline or some Q3 follow-up Forms may need to be skipped based on when the patient switched.
2. For Adynovate at Baseline: questions specifically relate to their previous factor use prior to Adynovate, and should be answered accordingly, even if more than 3 months has elapsed.
3. If subject completes cycle prior to 1 Year, complete the Module form(s) at End of Cycle.
4. EQ5D must be completed in person (not by phone).

Screening and Follow-up Guidelines

Screening

- Identify patients planning to switch soon (within 1 month)
- Screening can be performed prior to seeing patient for Consent to determine Eligibility
- A Screening 'Visit' may not be needed with subject/family
  - No tests to determine eligibility are required by protocol, other than Inhibitor test to establish baseline, prior to switch

ATHN 2 Eligibility

Key Date: Products approved by FDA after January 1, 2013

- Switching to a recently approved Factor Product
  - Factor VIII: Adynovate® Afstyla® Eloctate® Kovaltry® NovoEight® Nuwiq®
  - Factor IX: Alprolix® Idelvion® Rixubis® Xinity®
  - Additional products in the pipeline
  - Patients switching to a previously approved product (i.e, Advate) are not eligible
- Contact patient to confirm Factor Switch Date and enter onto Factor Switch Form in Study Manager.
- Eligibility criteria apply to all cycles, not just Cycle 1.
  - Good practice to recheck Eligibility if patient switches again and is entering Cycle 2 or higher

Q3 Phone Follow-up Timing

Based on Factor Switch Date and Number of Exposures

- Q3 Month Follow-up intervals are based on the Factor Switch Date. For example:
  - Patient Sam – Sam consented on 12/1/15 for Arm B
  - Date of Switch to Eloctate was 10/1/15
  - Follow-up: Sam will be followed prospectively every 3 months from 10/1/15. Also, based on the consent date of December 1st 2015, Sam will be eligible for all 4 (four) Q3 forms
  - The first Q3 follow-up would be due 1/1/16 (+/- 2 weeks)

Study Visit and Exposure Day Calculator

Infusion Schedule and Arm	Factor Switch Date	Assessment	Visit Window	Projected Date of Visit	Actual Date of Visit	Notes/Waived
[ ] 3 per week [ ] Arm A or [ ] Arm B	__/__/____	10 ED	3 weeks *2.5 to 4 weeks*	__/__/____	__/__/____	[ ] Waived Arm B
		Q3 Month Follow-up	12 weeks *10 to 14 weeks or 2.5 to 3.5 months*	__/__/____	__/__/____	[ ] Waived Arm B
		50 ED	16.5 weeks *16 to 17 weeks or 4 to 4.1 months*	__/__/____	__/__/____	[ ] Waived Arm B
		Q6 Month Follow-up	24 weeks *22 to 26 weeks or 5.5 to 6.5 months*	__/__/____	__/__/____	[ ] Waived Arm B

Site Data Management

- Collect data on printed CRFs
  - Some forms may be used as Source Documentation
- Enter data within 2 weeks of visit
  - Site Payments are based on forms submitted to Study Manager
  - Do not send paper forms to ATHN
- Clinical Manager will pre-populate available data

Available Resources

- Support@athn.org
- Study Manager
  - Provides access to Study Documents, Tools, eCRFs, etc.
- Manual of Operations
  - Additional information and resources to assist with the study conduct, and training new staff joining the HTC during study.

Available Resources

Available via Dropbox and Study Manager

- Recruitment Materials available in English and Spanish
  - ATHN 2 Brochure
    - Supply available by request and/or Site can print and add contact information
  - Powerpoint Slides for local and regional meetings
  - Recruitment Phone Script
- ICF Translated into Spanish (WIRB approved)
- All Study Documents, including Memos, Presentations

Study Plans

- Follow-up on recommendations from Breakfast Breakout Session and Best Practices presentations (J. Kadosh and E. Cockrell)
- Implementation of additional Product-Specific Modules for newly approved Factor Replacement Products
- Quarterly Site Calls
- Publications Subcommittee underway

Questions and Discussion after Site Presentations

Thank you!

athn™ american thrombosis & hemostasis network | 10 CELEBRATING ten years

ATHN 2 RESEARCH STUDY

Site Best Practices for ATHN 2

athn™ american thrombosis & hemostasis network | 10 CELEBRATING ten years

ATHN 2 RESEARCH STUDY